Economy July 26, 2026 06:27 AM

India Secures Exemptions for 45% of U.S.-Bound Exports in Latest Tariff Round

Negotiations place key sectors including pharmaceuticals, electronics and metals in a lower tariff category under the U.S. framework

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn

India said it obtained tariff exemptions for roughly 45% of its exports to the United States after trade talks placed those goods in a lower category under President Donald Trump's trade framework. Exempt items include generic medicines, smartphones, steel, aluminium and auto parts; the remaining 55% of exports will face an additional 10% U.S. levy. New Delhi says its tariff levels remain lower than those applied to many other economies covered by the U.S. measures and that discussions with Washington on a broader agreement continue.

India Secures Exemptions for 45% of U.S.-Bound Exports in Latest Tariff Round
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • India said roughly 45% of its U.S.-bound exports are exempt from the recently announced additional 10% U.S. tariff.
  • Exempt categories include generic medicines, smartphones, steel, aluminium and auto parts, offering a potential competitive advantage to exporters in those sectors.
  • The remaining 55% of exports will face the extra 10% duty; India says its tariff rates remain lower than those applied to many other economies covered by the U.S. measures.

India announced on Saturday that products representing about 45% of its exports to the United States will not be subject to the recent round of additional U.S. tariffs after bilateral trade negotiations led to a lower tariff designation under President Donald Trump's trade framework.

The Ministry of Commerce and Industry said in a dated statement on Saturday that this exempted share includes a range of goods such as generic medicines, smartphones, steel, aluminium and auto parts. These products will not incur the extra 10% levy that Washington introduced last week.

New Delhi said the exemptions should help Indian exporters preserve a competitive edge at a time when trade barriers are rising and future U.S. tariff policy remains uncertain. The government also said talks with Washington are ongoing as the two sides seek an early conclusion on a broader bilateral trade agreement.

Despite the exemptions, the ministry confirmed that the other 55% of Indian exports to the United States will be liable for the additional 10% duty. The statement noted that India’s tariff rates are still lower than those applied to many other economies covered by the U.S. measures.

Trade discussions between New Delhi and Washington have been underway since last year. A preliminary agreement reached in February had foreseen an 18% tariff on Indian goods, but later legal developments in the United States altered the path forward. The ministry’s statement referenced a U.S. Supreme Court ruling that invalidated the reciprocal tariff framework tied to President Trump, a change that affected the negotiating environment.

The announcement comes amid particular concern over possible U.S. tariffs on generic medicines, an issue that has weighed on Indian pharmaceutical companies for whom the United States is the largest export market. Earlier this month India publicly rejected suggestions it could face steeper tariffs tied to labour-related matters, saying the United States had not provided evidence that India lacked adequate safeguards against forced labour.

For exporters of affected goods, the mix of exemptions and levies will shape competitiveness in U.S. markets going forward. New Delhi framed the outcome as a partial victory while underscoring that negotiations remain active and that broader agreement discussions are ongoing.


Sectors mentioned: pharmaceuticals, electronics (smartphones), steel, aluminium, auto parts.

Risks

  • More than half of Indian exports to the U.S. - 55% - will be subject to the new 10% levy, increasing cost pressure on affected exporters and supply chains (impacts: manufacturing, commodities, supply chain costs).
  • Ongoing negotiations leave outcomes uncertain - broader bilateral agreement talks continue and legal developments in the U.S., including a Supreme Court ruling that invalidated the reciprocal tariff framework, have changed the negotiating environment (impacts: trade policy, market access).
  • Concerns persist over potential U.S. tariffs on generic medicines, a sector for which the U.S. is India’s largest export market, creating downside risk for Indian pharmaceutical exporters (impacts: pharmaceuticals, healthcare supplies).

More from Economy

Goldman Sees Modest Changes From Warsh's Fed Task Forces, Not a Overhaul Jul 26, 2026 Firefighters Battle Fast-Moving Blazes as Evacuations Expand Near Bordeaux Jul 26, 2026 US, Japan Join Philippine Naval Drills Amid Ongoing South China Sea Confrontations Jul 26, 2026 Burnham Signals Willingness to Push Back Against Trump When UK Interests Require It Jul 26, 2026 Can China’s inventory run-down Keep Oil Prices in Check? Jul 26, 2026